FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Business Trip
English - June 21, 2024 12:00 - 56 minutes - 39.1 MBEntrepreneurship Business Health & Fitness Mental Health psychedelics psychedelic psychedelic startups mental health wellness human flourishing Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Investing in New Frontiers of Mental Health (Live at SXSW)
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.
Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.
In this episode, we discuss:
The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic clinical trialsPotential impacts on the broader psychedelic medicine industryThe future of psychedelic-assisted psychotherapy protocolsNeuroplastogen development and non-hallucinogenic approachesChallenges around therapy, safety, and regulatory pathways for psychedelic medicinesCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank